Equities researchers at StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a report issued on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Alimera Sciences in a research report on Thursday, February 23rd. Alliance Global Partners cut shares of Alimera Sciences from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $11.00 to $4.50 in a research report on Monday, November 21st.
Alimera Sciences Stock Up 8.9 %
Shares of Alimera Sciences stock opened at $2.20 on Friday. The stock has a market capitalization of $15.40 million, a P/E ratio of -0.83 and a beta of 1.42. The company has a 50-day simple moving average of $2.57 and a 200 day simple moving average of $4.22. Alimera Sciences has a 12-month low of $1.86 and a 12-month high of $7.92.
Institutional Inflows and Outflows
Alimera Sciences Company Profile
Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.